addressing the role of parp inhibitors in different breast cancer settings
Published 6 years ago • 118 plays • Length 1:13Download video MP4
Download video MP3
Similar videos
-
3:50
debu tripathy, md, describes the evolving role of parp inhibitors in breast cancer patients
-
1:46
combination of veliparib and chemotherapy in brca-positive breast cancer
-
1:32:38
managed care implications of the expanding role of parp inhibitors in oncology
-
58:46
learn all about parp inhibitors with dr jon krell, consultant medical oncologist
-
7:42
parp inhibitors in other subtypes of breast cancer
-
5:13
practical use of parp inhibitors in ovarian cancer
-
3:46
case 4: parp inhibitors for treating brca triple-negative breast cancer
-
3:31
distinguishing between parp inhibitors in breast cancer
-
4:59
future role of parp inhibition in brca breast cancer
-
8:50
case 4: chemotherapy or parp inhibitors for brca tnbc
-
1:12
dr. joanne blum on the function of talazoparib in locally advanced and/or metastatic breast cancer
-
1:27
parp inhibition improves outcomes in patients with brca-mutated ovarian cancer
-
3:58
brca breast cancer: the advent of parp inhibitors
-
1:13:00
expanding the benefits of parp inhibitors to more patients with breast cancer and earlier settings
-
1:58
discussing targeted treatment with parp inhibitors for brca-mutant patients across tumor types
-
2:08
dr. lorusso on parp inhibitors in triple-negative breast cancer
-
8:04
chemotherapy and parp inhibitors in bc
-
1:17
the complexity of the parp inhibitor landscape in ovarian cancer
-
1:16
parp inhibitors improve outcomes, qol in breast cancer